COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-analysis of Individual Participant Data From Five Randomized Trials

BACKGROUND. Monoclonal antibody and antiviral treatments for COVID-19 disease remain largely unavailable worldwide, and existing monoclonal antibodies may be less active against circulating omicron variants. Although treatment with COVID-19 convalescent plasma (CCP) is promising, randomized clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Levine, Adam C., Fukuta, Yuriko, Huaman, Moises A., Ou, Jiangda, Meisenberg, Barry R., Patel, Bela, Paxton, James H., Hanley, Daniel F., Rijnders, Bart JA, Gharbharan, Arvind, Rokx, Casper, Zwaginga, Jaap Jan, Alemany, Andrea, Mitjà, Oriol, Ouchi, Dan, Millat-Martinez, Pere, Durkalski-Mauldin, Valerie, Korley, Frederick K., Dumont, Larry J., Callaway, Clifton W., Libster, Romina, Marc, Gonzalo Perez, Wappner, Diego, Esteban, Ignacio, Polack, Fernando, Sullivan, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774226/
https://www.ncbi.nlm.nih.gov/pubmed/36561181
http://dx.doi.org/10.1101/2022.12.16.22283585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774226/
https://www.ncbi.nlm.nih.gov/pubmed/36561181
http://dx.doi.org/10.1101/2022.12.16.22283585

Ejemplares similares